河南医生捐献造血干细胞救人 此前已坚持献血20年

2017-10-18 韩章云 中新网

10月17日,河南登封的儿科医生郑利昌顺利完成造血干细胞捐献,为一位22岁白血病患者送去“生命种子”,成为河南省第643位造血干细胞捐献者。

10月17日,河南登封的儿科医生郑利昌顺利完成造血干细胞捐献,为一位22岁白血病患者送去“生命种子”,成为河南省第643位造血干细胞捐献者。而在过去的20年里,郑利昌坚持无偿献血,家里的献血证多得数不清。在郑利昌看来,无论是献血还是捐造血干细胞,他只是单纯地想帮别人一把。


图为郑利昌成为河南省第643位造血干细胞捐献志愿者,中国造血干细胞捐献者资料库河南省分库负责人张书环向其颁发证书。

10月17日,在河南省肿瘤医院的造血干细胞采集室,郑利昌在妻子的陪伴下进行造血干细胞采集。今年38岁的郑利昌是登封怀宇堂医院的一位儿科医生,医者父母心,多年的工作中,经郑利昌之手得以摆脱病痛的孩子不计其数,也让他更能理解病痛给患者及家属带去的是多么沉重的负担。

作为一名医生,郑利昌有坚持献血的习惯。从身份证上的日期满18周岁开始,他每年都坚持无偿献血,20年来,家里面的献血证攒了厚厚一摞,捐献次数多到郑利昌自己都记不起来了。也是在献血的过程中,郑利昌了解了捐献造血干细胞的意义,于2015年5月6日加入了中国造血干细胞捐献者资料库,期待着有一天能用自己的“生命种子”挽救别人的生命。

2017年3月,正在工作中的郑利昌接到了郑州市红十字会工作人员打来的电话,被告知自己与一位白血病人初步配型成功,这个消息让郑利昌十分惊喜:“能配型成功对我来说是太大的惊喜,因为这是救人一命的好事,真的没有丝毫犹豫,我必须捐献。”而郑利昌也顺利地完成了后续的一系列体检,直至捐献的这一天。

在郑利昌做造血干细胞采集时,对方患者所在医院的志愿者为他送来了一份特殊的礼物:一封由患者亲笔书写感谢信。

“真心谢谢您感天动地的大爱和无私奉献的精神,我相信当您的造血干细胞输入到我的血液和骨髓中时,22岁的我和病魔斗争两年的年轻生命必将迎来新生,我将竭尽所能去回报社会帮助他人,传递您的爱心,学习您的精神……”患者朴实的话语让郑利昌眼眶湿润、良久默默无言。

“我捐献造血干细胞不图名不图利,只是单纯想救这个年轻人一命,就这么简单。”对于这位未曾谋面的年轻人,郑利昌也送上自己的真挚祝福:“人生路还很长,你要早点好起来,去体验不同的精彩。”

最终,郑利昌成功捐献造血干细胞,成为全国第6809位、河南省第643位、郑州市第243位造血干细胞捐献志愿者。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1758663, encodeId=ae911e5866360, content=<a href='/topic/show?id=0fc55652546' target=_blank style='color:#2F92EE;'>#捐献#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56525, encryptionId=0fc55652546, topicName=捐献)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b2a37353309, createdName=新生儿张玉军, createdTime=Sun Dec 31 14:06:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271417, encodeId=ff5b12e141732, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95001, encryptionId=a0ff950018f, topicName=造血干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Thu Oct 19 23:06:00 CST 2017, time=2017-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494568, encodeId=a483149456813, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Thu Oct 19 23:06:00 CST 2017, time=2017-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589162, encodeId=fedc1589162c9, content=<a href='/topic/show?id=db555e545fb' target=_blank style='color:#2F92EE;'>#救人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57545, encryptionId=db555e545fb, topicName=救人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=782b17684927, createdName=ay2006fy, createdTime=Thu Oct 19 23:06:00 CST 2017, time=2017-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254402, encodeId=b57e254402dd, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KiblTyxD95ExbzUoCVcRuhPibXboL28wicFMTXUhCA0RWCyQZYC5Na3ap7CxjialMkB50VEJ0XToQQTC/0, createdBy=470c1945776, createdName=方舒, createdTime=Thu Oct 19 22:26:25 CST 2017, time=2017-10-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1758663, encodeId=ae911e5866360, content=<a href='/topic/show?id=0fc55652546' target=_blank style='color:#2F92EE;'>#捐献#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56525, encryptionId=0fc55652546, topicName=捐献)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b2a37353309, createdName=新生儿张玉军, createdTime=Sun Dec 31 14:06:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271417, encodeId=ff5b12e141732, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95001, encryptionId=a0ff950018f, topicName=造血干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Thu Oct 19 23:06:00 CST 2017, time=2017-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494568, encodeId=a483149456813, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Thu Oct 19 23:06:00 CST 2017, time=2017-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589162, encodeId=fedc1589162c9, content=<a href='/topic/show?id=db555e545fb' target=_blank style='color:#2F92EE;'>#救人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57545, encryptionId=db555e545fb, topicName=救人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=782b17684927, createdName=ay2006fy, createdTime=Thu Oct 19 23:06:00 CST 2017, time=2017-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254402, encodeId=b57e254402dd, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KiblTyxD95ExbzUoCVcRuhPibXboL28wicFMTXUhCA0RWCyQZYC5Na3ap7CxjialMkB50VEJ0XToQQTC/0, createdBy=470c1945776, createdName=方舒, createdTime=Thu Oct 19 22:26:25 CST 2017, time=2017-10-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1758663, encodeId=ae911e5866360, content=<a href='/topic/show?id=0fc55652546' target=_blank style='color:#2F92EE;'>#捐献#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56525, encryptionId=0fc55652546, topicName=捐献)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b2a37353309, createdName=新生儿张玉军, createdTime=Sun Dec 31 14:06:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271417, encodeId=ff5b12e141732, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95001, encryptionId=a0ff950018f, topicName=造血干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Thu Oct 19 23:06:00 CST 2017, time=2017-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494568, encodeId=a483149456813, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Thu Oct 19 23:06:00 CST 2017, time=2017-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589162, encodeId=fedc1589162c9, content=<a href='/topic/show?id=db555e545fb' target=_blank style='color:#2F92EE;'>#救人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57545, encryptionId=db555e545fb, topicName=救人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=782b17684927, createdName=ay2006fy, createdTime=Thu Oct 19 23:06:00 CST 2017, time=2017-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254402, encodeId=b57e254402dd, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KiblTyxD95ExbzUoCVcRuhPibXboL28wicFMTXUhCA0RWCyQZYC5Na3ap7CxjialMkB50VEJ0XToQQTC/0, createdBy=470c1945776, createdName=方舒, createdTime=Thu Oct 19 22:26:25 CST 2017, time=2017-10-19, status=1, ipAttribution=)]
    2017-10-19 俅侠
  4. [GetPortalCommentsPageByObjectIdResponse(id=1758663, encodeId=ae911e5866360, content=<a href='/topic/show?id=0fc55652546' target=_blank style='color:#2F92EE;'>#捐献#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56525, encryptionId=0fc55652546, topicName=捐献)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b2a37353309, createdName=新生儿张玉军, createdTime=Sun Dec 31 14:06:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271417, encodeId=ff5b12e141732, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95001, encryptionId=a0ff950018f, topicName=造血干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Thu Oct 19 23:06:00 CST 2017, time=2017-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494568, encodeId=a483149456813, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Thu Oct 19 23:06:00 CST 2017, time=2017-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589162, encodeId=fedc1589162c9, content=<a href='/topic/show?id=db555e545fb' target=_blank style='color:#2F92EE;'>#救人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57545, encryptionId=db555e545fb, topicName=救人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=782b17684927, createdName=ay2006fy, createdTime=Thu Oct 19 23:06:00 CST 2017, time=2017-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254402, encodeId=b57e254402dd, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KiblTyxD95ExbzUoCVcRuhPibXboL28wicFMTXUhCA0RWCyQZYC5Na3ap7CxjialMkB50VEJ0XToQQTC/0, createdBy=470c1945776, createdName=方舒, createdTime=Thu Oct 19 22:26:25 CST 2017, time=2017-10-19, status=1, ipAttribution=)]
    2017-10-19 ay2006fy
  5. [GetPortalCommentsPageByObjectIdResponse(id=1758663, encodeId=ae911e5866360, content=<a href='/topic/show?id=0fc55652546' target=_blank style='color:#2F92EE;'>#捐献#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56525, encryptionId=0fc55652546, topicName=捐献)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b2a37353309, createdName=新生儿张玉军, createdTime=Sun Dec 31 14:06:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271417, encodeId=ff5b12e141732, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95001, encryptionId=a0ff950018f, topicName=造血干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Thu Oct 19 23:06:00 CST 2017, time=2017-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494568, encodeId=a483149456813, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Thu Oct 19 23:06:00 CST 2017, time=2017-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589162, encodeId=fedc1589162c9, content=<a href='/topic/show?id=db555e545fb' target=_blank style='color:#2F92EE;'>#救人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57545, encryptionId=db555e545fb, topicName=救人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=782b17684927, createdName=ay2006fy, createdTime=Thu Oct 19 23:06:00 CST 2017, time=2017-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254402, encodeId=b57e254402dd, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KiblTyxD95ExbzUoCVcRuhPibXboL28wicFMTXUhCA0RWCyQZYC5Na3ap7CxjialMkB50VEJ0XToQQTC/0, createdBy=470c1945776, createdName=方舒, createdTime=Thu Oct 19 22:26:25 CST 2017, time=2017-10-19, status=1, ipAttribution=)]
    2017-10-19 方舒

    学习

    0

相关资讯

Blood:来自范可尼贫血患者的经基因校正过的CD34+细胞的移植情况及增值优势。

范可尼贫血(Fanconi anemia)是一种罕见的常染色体隐形遗传性血液系统疾病,属于先天性再生障碍性贫血。该类病人除了典型再障表现外,还伴有多发性的先天畸形(皮肤棕色色素沉着、骨骼畸形、性发育不全等)。中心点:通过对CD34+细胞的优化采集和短期转化,首次证明可对范可尼贫血再生细胞进行表型校正。优化范可尼贫血患者的CD34+细胞的体外基因疗法,稳固表型校正后的重回输细胞的增殖优势。摘要:既往

NATURE:我国科学家揭示m6A调控造血干细胞命运决定新机制”

血液,是生命的源泉。不断流动的血细胞既可以运输营养物质,又起到免疫保护作用。在发育过程中,所有的血细胞都来源于胚胎期产生的造血干细胞。随后,这些干细胞会迁移至成体骨髓以维持终身造血,此外,它们也是骨髓移植术治疗恶性血液疾病的核心组分。但在临床上,造血干细胞来源匮乏一直是制约血液疾病治疗的瓶颈。因此,探索造血干细胞的体内发育机制以及建立体外诱导扩增方案便成为当今科学界的研究热点。目前,人们对于造血干

Leukemia:中国学者研究结论挑战造血干细胞移植经典法则

近日,国际著名期刊《白血病》(Leukemia)在线发表了北京大学血液病研究所、北京大学人民医院黄晓军教授课题组完成的“急性白血病首次缓解期异基因造血干细胞移植供者选择”前瞻性临床研究。这一研究成果用实例挑战了造血干细胞移植“HLA全合同胞始终作为首选供者”的经典法则,提出“单倍型供者可部分取代经典的全合同胞供者成为移植首选”的新观点。

看哭了!美女自曝捐献造血干细胞日志,万名网友围观点赞

18岁开始,每年都在固定献血。直到准备捐献之前累计献了3200ml,别看我刚卡了一百斤体重,每次也抽400ml封顶的。09年一次献血的时候,顺便留了两管血样,入了中华骨髓库,十万分之一配型成功概率,我当时猜没那么巧吧。

Cell Stem Cell:造血干细胞直接响应感染,既“杀敌”也“自损”

造血干细胞是血液系统中的成体干细胞,具有自我更新、多向分化的潜能。造血干细胞可以分化形成各类成熟血细胞,以此满足生理需求和调节各细胞组分之间的平衡。如果发生严重感染,造血干细胞会生成更多的白细胞以抵抗病原物。

上海造血干细胞捐献史上动员时间最短,志愿者8小时完成签署

7月1日,炎热的午后,一名造血干细胞捐献者资料库工作人员的手机响了。信息显示,一名白血病患者生命危在旦夕,急需造血干细胞移植。2日,造血干细胞志愿者朱归仁来到医院,进行了动员剂的注射。6日,朱归仁完成了一次造血干细胞采集。也成为上海造血干细胞捐献20多年历史上“动员”时间最短的志愿者,仅仅用了8小时完成签署,5天就可以完成采集。这是对志愿者捐献意愿的考验,更是一场和死神较量的赛跑。“救人命要紧,同